Global Startups Insights
Lets your startup
Funding News, Massachusetts, USA Startup Funding News

Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments

November 17, 2026
By
Loren Baker
Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments

Kernal Bio, a biotechnology company developing AI-powered genetic medicines, has announced a strategic partnership and investment from the Institute for Follicular Lymphoma Innovation (IFLI) to accelerate the development of its next-generation CAR-T therapy, KR-402.

The investment will support the development of KR-402, an mRNA-based CAR-T treatment candidate designed for blood cancers, including follicular lymphoma, and autoimmune diseases such as multiple sclerosis.

“We’re honored to partner with IFLI to advance KR‑402 toward the clinic,” said Yusuf Erkul, M.D., M.B.A., Co‑Founder and CEO of Kernal Bio. “This partnership brings together organizations with a shared commitment to developing new treatment options for people living with follicular lymphoma, and to ultimately finding a cure.”

The partnership builds on Kernal Bio’s recent award of up to $48 million from the Advanced Research Projects Agency for Health (ARPA-H) to support KR-402. The company has also received support from NVIDIA, Microsoft, and Eli Lilly through the Lilly Gateway Labs accelerator.

Kernal Bio is developing a technology that programs cells directly inside the human body using AI-designed messenger RNA (mRNA) and targeted lipid nanoparticles (LNPs). Its proprietary mRNA 2.0 platform combines cell-selective mRNA with antibody-coated lipid nanoparticles to deliver therapeutic instructions to specific cells.

This approach aims to generate CAR-T cells directly inside the body, potentially reducing the need for traditional CAR-T manufacturing, which involves collecting, modifying, and processing a patient’s cells outside the body. It could help make advanced cell therapies less complex and more accessible.

“With support from IFLI, ARPA-H, and our ecosystem of partners, we are accelerating the transformation of CAR‑T therapy to an in vivo approach that could improve the patient journey and expand patient access for serious diseases,” said Manfred Kraus, Ph.D., Senior Vice President of R&D Therapeutics at Kernal Bio.

“IFLI is proud to support the development of KR-402 as part of our commitment to catalyzing next-generation treatments for follicular lymphoma,” said David McCullagh, Managing Director of IFLI. “Based on compelling preclinical data, Kernal Bio’s in vivo CAR-T platform has the potential to address important limitations of current approaches, including lengthy manufacturing timelines and treatment complexity, and ultimately broaden access to transformative immunotherapies for the follicular lymphoma.”

Alongside the partnership, Kernal Bio announced several leadership and board appointments to strengthen its scientific and business operations.

Kirsten Kester has joined as Chief Business Officer. She previously served as Senior Vice President at Obsidian Therapeutics, where she worked on corporate strategy, fundraising, and strategic partnerships. Sieun K. Barnes, Ph.D., has been appointed Director of Process Development (CMC). She previously worked at Moderna, leading mRNA and lipid nanoparticle development programs.

The company has also expanded its Board of Directors with the appointment of Stuart Chaffee, Ph.D., a biotechnology entrepreneur and CEO of Forward Therapeutics. Carol O’Hear, M.D., Ph.D., Chief Medical Officer of Exelixis, and Patrick Lundgren, Ph.D., of Hummingbird Ventures, have joined as board observers.

Kernal Bio also appointed several scientific and industry experts to its Advisory Board, bringing experience in immunology, rheumatology, neurology, finance, and business development.

Founded by experts from MIT, Harvard, Merck, and Bristol Myers Squibb, Kernal Bio is developing in vivo CAR-T therapies for autoimmune diseases and blood cancers. The company has a team with experience behind three FDA-approved therapies and holds more than 120 patents.

With the new strategic investment from IFLI and continued support from ARPA-H and other technology partners, Kernal Bio aims to accelerate KR-402 development and advance its AI-powered platform for next-generation genetic medicines.

Recommended Stories for You